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Fourier Transform Infrared (FT-IR) and Raman spectroscopy were used to study the molecular 
structure of the recombinant monoclonal antibody and anti-CD20-conjugates which are intended to be 
used as anti-cancer therapeutic agents. We characterized the secondary structure of a therapeutic 
immunoconjugate of rituximab, formulated with three different bifunctional chelating agents (p-SCN-Bn-
DOTA, p-SCN-Bn-DTPA, and 1B4M-DTPA) and labeled with non-radioactive lutetium and yttrium. The 
secondary structure content of all three immunoconjugates was assessed to be similar to that of unlabeled 
antibody. In addition, no significant changes upon lyophilizing procedures were observed. The results 
demonstrate that amide bands could be used as analytical tool which provides a quick and reliable way 
for screening of protein pharmaceuticals during the development of lyophilized formulations. 
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ЕВАЛУАЦИЈА НА ИМУНОКОНЈУГАТИ НА РИТУКСИМАБ  
ОБЕЛЕЖАНИ СО НЕРАДИОАКТИВНИ ЛУТЕЦИУМ И ИТРИУМ  
– СТУДИЈА СО ВИБРАЦИОНА СПЕКТРОСКОПИЈА 
 
За испитување на молекулската структура на рекомбинантно моноклонално антитело и 
анти-CD20-конјугати наменети за употреба како антиканцерни терапевтски агенси е користена 
инфрацрвена (ИЦ) и раманска спектроскопија. Секундарната структура на терапевтски 
имуноконјугат на ритуксимаб е карактеризирана во негови формулации со три различни 
бифункционални хелирачки агенси (p-SCN-Bn-DOTA, p-SCN-Bn-DTPA, 1B4M-DTPA) обележани 
со нерадиоактивни лутециум и итриум. Најдено е дека секундарната структура на сите три типа 
имуноконјугати е слична со таа на необележаното антитело. Освен тоа, не беа забележани 
значајни промени после процесот на лиофилизација на имуноконјугатите. Добиените резултати 
покажаа дека амидните вибрациони ленти можат да бидат искористени како аналитичка алатка 
која овозможува брз и веродостоен начин за скрининг на протеински лекови во текот на процесот 
на развој на лиофилизирани формулации. 
 
Клучни зборови: ритуксимаб; бифункционални хелирачки агенси; инфрацрвена и раманска 
спектроскопија 
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1. INTRODUCTION 
 
Monoclonal antibodies are among the main 
categories of molecules used in targeted therapy. In 
radioimmunotherapy, monoclonal antibodies 
(mAbs) are attached to a therapeutic radioisotope, 
where these antibodies act as a carrier and target 
tumor cells [1]. An inherently radiosensitive malig-
nancy, known as Non-Hodgkin’s lymphoma (NHL), 
has provided the basis for radioimmunotherapy. 
CD20 receptor has proven to be an excellent target 
for the treatment of B-cell lymphoma [2]. More than 
90% of B-cell lymphoma cells express CD20, but it 
is not promoted on cells in stem and progenitor cell 
pools. Rituximab (Rituxan
TM
, Genentech Inc., South 
San Francisco, CA, and Biogen-IDEC Pharmaceuti-
cal Corp, San Diego, CA), a mouse-human chimeric 
mAb produced in CHO cells that reacts with CD20, 
has proven to be highly effective and relatively non-
toxic in the treatment of B-cell malignancies [3, 4]. 
Until now, two anti-CD mAb products have been 
approved in the United States for the treatment of B-
cell lymphomas: the radiolabeled antibodies Y-90 
ibritumomab tiuxetan (Zevalin™, Biogen-IDEC 
Pharmaceuticals, San Diego, CA) and I-131 tositu-
momab (Bexxar™, GlaxoSmithKline, Research 
Triangle Park, NC) [5, 6]. Radioimmunotherapy is 
found to be more advantageous compared to unla-
beled therapeutic antibodies, given the additive ef-
fect of radiation-induced cytotoxicity and the ability 
of the associated radioactivity to kill the adjoining 
cancerous tumor cells that may not have bound the 
radiolabeled antibody [7]. 
The success in application of rituximab is 
highly dependent on the physical and chemical 
properties of the radioisotope attached. Among the 
various radionuclides, radiolanthanides are of par-
ticular interest and several isotopes are available: 
the low energy β-emitter 177Lu, medium energy β-
emitters (
153Sm), and the high energy β-emitter 
166
Ho. Depending on the tumor size and location, 
the choice of β-emitter may be different [8]. For 
systemic cancer radiotherapy, 
90
Y is of particular 
interest due to its high-energy pure β-particle emis-
sion. 
90
Y has a half-life of 2.7 days, which is short 
enough to achieve a critical dose rate and, at the 
same time, durable enough to allow the manufac-
ture, transportation and delivery of the radiophar-
maceutical for clinical use. The specific activity for 
90
Y is very high, and is well suited for the devel-
opment of receptor-based therapeutic radiophar-
maceuticals [9]. 
177Lu is a β- and γ-emitter radio-
nuclide (half-life 6.65 days) whose short-range β-
particles (0.04–1.8 mm) with low energy (0.497 
MeV, 78.7% abundance) are suitable for therapeu-
tic purposes. Moreover, the main γ-photons of 
177
Lu (0.208 MeV, 11% abundance) are appropri-
ate for gamma imaging and can be used for 
dosimetric estimations in humans. Due to its prop-
er characteristics, 
177
Lu is being increasingly used 
in research studies [10–13]. Over the years, a num-
ber of chelating agents have also been investigated 
for labeling proteins and peptides with radioiso-
topes. The most widely investigated agents are vari-
ous derivatives of the acyclic agent diethylene 
triamine pentaacetic acid (DTPA) and the 
macrocyclic agent 1,4,7,10-tetraazacyclododecane-
1,4,7,10-tetraacetic acid (DOTA) [14]. In some of 
these investigations, the labeling of antibodies and 
their fragments with 
177
Lu has been achieved using 
2-(4-isothioyanatobenzyl)diethylenetriaminepenta-
acetic acid (p-SCN-Bn-DTPA), cyclic DTPA 
dianhydride and 1,4,7,10-tetraaza-N-(1-carboxy-3-
(4-nitrophenyl)propyl)-N′, N′′,N′′′-tris(acetic acid) 
cyclododecane (PA-DOTA) [10–12, 15–18]. Alt-
hough the preparations of these and other deriva-
tives of DOTA and DTPA radioimmunoconjugates 
have been reported [11, 12, 14], chemical charac-
teristics, stability and the biodistribution of the 
prepared radioimmunoconjugates have not been 
examined in detail.  
Therapeutic monoclonal antibodies are very 
complex molecular structures that are joined to-
gether with weak, non-covalent or strong covalent 
disulfide bonds. Keeping the bonding integrity is 
of utmost importance for the physicochemical sta-
bility and immunological potential. Therapeutic 
proteins are usually formulated in aqueous solution 
to allow ease of use, but it is also known that an 
aqueous environment can accelerate many degra-
dation processes [19, 20]. The common approach 
to the stabilization of therapeutic proteins is 
lyophilization, which is a reliable process that can 
assure the product sterility requirements without 
the stress of thermal sterilization [21].  
In order to obtain 
90
Y- and 
177
Lu-anti-CD20 
radioimmunoconjugates for using in diagnos-
tic/therapeutic studies, different bifunctional che-
lating agents-anti-CD20 (rituximab) (BFCA-rituxi-
mab) were labeled with non-radioactive Y and Lu 
for preliminary physicochemical characterization. 
This work aims to examine ready-to-label lyophi-
lized rituximab immunoconjugates with different 
BFCAs, 2-(4-isothiocyanatobenzyl)-1,4,7,10 tetra-
azacyclododecane-tetraacetic acid (p-SCN-Bn-
DOTA), 2-(4-isothiocyanatobenzyl) diethylenetri-
amine-pentaacetic acid (p-SCN-Bn-DTPA) and 2-
(4-isothiocyanatobenzyl)-6-methyl-diethylene-tria-
minepentaacetic acid (1B4M-DTPA) by infrared 
(IR) and Raman spectroscopy to reveal the possi-
ble post-conjugation, post-lyophilization and post-
                    Evaluation of non-radioactive lutetium- and yttrium-labeled immunoconjugates of rituximab…                   353 
Maced. J. Chem. Chem. Eng. 34 (2), 351–362 (2015) 
labeling modifications. The main goal was to de-
termine the suitability of preparation and labeling 
procedures to obtain kit formulations ready for ra-
dioactive labeling. In fact, we examined the possi-
bility to assess some relevant structural elements of 
the immunoconjugates by FT-IR and Raman spec-
troscopy “fingerprint” techniques. 
 
2. MATERIALS AND METHODS 
 
2.1. Materials 
 
All three conjugation agents with ≥94% pu-
rity were obtained from Macrocyclics Inc. (NJ, 
USA). Rituximab was purified from a commercial 
sample (Mabthera
®
), purchased from Roche Co, 
CA, USA, using ultrafiltration (Ultracel
® – 30K, 
Millipore, Ireland) for concentration and buffer 
exchange to sterile 0.1 M PBS, pH 8.0.  
 
2.2. Conjugation of rituximab to three  
different BFCAs 
 
BFCAs were dissolved in 0.1 M PBS (pH 
8.0) to a concentration of 10 mg/ml. Calculated 
amounts of BFCA required to give a 20-fold molar 
excess over the amount of rituximab (10 mg/ml) 
were added to the antibody solution. The mixtures 
were incubated at 4 °C overnight with gentle shak-
ing. Purification was performed by rinsing the 
immunoconjugates with 0.05 M ammonium acetate 
(pH 7.0), in ultrafiltration devices (Ultracel
®
), until 
absorbance in the ultrafiltrate, set at 280 nm, was 
nearly zero. The concentrations were adjusted to 1 
mg/ml and solutions were lyophilized to solid state.  
 
2.3. Lyophilization process 
 
The lyophilization was performed by using 
Labconco Free Zone Stoppering Tray Dryer (USA), 
modifying the protocol described by Park et al. [22] 
as follows. The solutions of immunoconjugates 
were transferred to 10 ml (type I glass) tubing vials 
using a fill volume of 1 ml. The vials were partially 
covered with suitable stoppers and equally distribut-
ed on the shelves of the apparatus. In order to moni-
tor the temperature variations, thermocouples were 
placed in the center of each shelf using a blank vial. 
The samples were loaded at shelf temperature of 
5 °C. The temperature was then decreased to –40 °C 
at a rate of 0.40 °C/min and held for 3 h. An anneal-
ing step was included, at –15 °C, to allow complete 
crystallization, thus completing the freezing step in 
10 h. The primary drying was performed at –10 °C 
for 25 h. The secondary drying was performed at the 
shelf temperature of 25 °C for 11 h. Upon comple-
tion of the process, the vials were covered and kept 
at 4 °C until analysis.  
 
2.4. Labelling the BFCA-rituximab conjugates  
with non-radioactive Lu and Y 
 
BFCA-rituximab conjugates in the form of 
freeze-dried preparations were dissolved with ster-
ile saline, and subsequently labeled with 1.0709 µg 
LuCl3 [equivalent to maximum tolerated dose 
(MTD) for 
177
Lu (118.3 mCi)] or with 1.1555 mg 
YCl3 [equivalent to MTD for 
90
Y (28.37 mCi)] in a 
total volume of 1 ml at pH 7.0, before being incu-
bated for 30 min at room temperature (p-SCN-Bn-
DTPA-rituximab and 1B4M-DTPA-rituximab) and 
60 min at 40 °C (p-SCN-Bn-DOTA-rituximab). 
 
2.5. FT-IR and Raman spectroscopy 
 
FT-IR and Raman spectroscopy were ap-
plied for determination of protein secondary struc-
ture. FT-IR spectroscopy measurements were con-
ducted on PARAGON 1000 (Perkin Elmer) spec-
trophotometer in the spectral range 2000–500 cm–1 
and the plates were scanned three times to mini-
mize the influence of spotting variance. Attenuated 
Total Reflectance (ATR) spectra were acquired at 
a resolution of 4 cm
–1 
and 128 spectra were accu-
mulated in order to improve the signal-to-noise 
ratio. After spectral acquisition, data manipulation 
was performed with the Grams_32 software 
(Thermo Scientific). 
The room temperature Raman spectra 
(2000–400 cm–1) were recorded on a micro-Raman 
multichannel spectrometer Horiba JobinYvon 
LabRam 300 Infinity. The Raman effect was ob-
tained using 632.8 nm line from a He:Ne laser. An 
Olympus MPlanN confocal microscope with ×100 
objective for magnification was selected. The spec-
tral resolution was set to 4 cm
–1
. In order to focus 
the laser beam, a confocal hole of about 2 μm was 
used and the position on the sample surface was 
adjusted by using a motorized x-y stage. The Ra-
man shift was calibrated by using the Raman peak 
of silica located at 520.7 cm
–1
. The acquisition 
time and the accumulation number were set to 10 s 
and 10 scans, respectively. 
 
3. RESULTS AND DISCUSSION 
 
Structural and orientation changes are often 
a part of protein interactions due to various factors 
such as specific/nonspecific attachment, hydra-
tion/dehydration, and experimental conditions [23]. 
In order to assess the stability of monoclonal anti-
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bodies, this study was aimed at monitoring the 
changes in physicochemical properties of rituxi-
mab conjugates after lyophilization and non-
radioactive labeling. The structural formulae of 
BFCAs used for conjugation of the antibody are 
shown in Figure 1. 
 
 
Fig. 1. Structural formulae of BFCAs used for conjugation 
 
To obtain evidence for preserved secondary 
antibody structure (which is mandatory for thera-
peutic immunoconjugates) and possible post-non-
radioactive labelling modifications, a vibrational 
spectroscopic study was performed. Protein dena-
turation upon lyophilization is usually monitored 
by IR spectroscopy [24], although other methods 
such as mass spectroscopy [25], and Raman spec-
troscopy [26] are also applied. In this study, IR and 
Raman spectroscopy were used for extensive char-
acterization of the immunoconjugates of interest by 
monitoring molecular vibrations of the structural 
building units.  
IR and Raman spectroscopic applications for 
protein pharmaceuticals (in their native and dena-
tured state) include evaluation of the conformation 
changes, protein–protein interactions, protein ag-
gregation and protein–drug product characteriza-
tion. Vibrational spectra can be used to estimate 
the secondary structure of proteins by inspection of 
the frequencies at which the amide bonds absorb 
infrared radiation (Table 1) [27–30].  
The experimental IR spectra (in the region 
2000–500 cm–1) of investigated compounds are 
displayed in Figure 2 and Figure 3, whereas the 
band assignment is given in Table 2. On the other 
hand, the obtained Raman spectra (2000–400 cm–1 
region) of unlabeled and non-radioactively labeled 
immunoconjugates are presented in Figure 4 and 
Figure 5, with the corresponding band assignments 
listed in Table 3. 
T a b l e  1  
 
Characteristic vibrational bands  
for the secondary structure of proteins  
(according to Ref. [29] and [30]) 
 
Designation and description Approximate frequency 
(cm
–1
) 
Amide I 
(C=O stretching)  
Conformation determining 
band position: 
α-helix  
Antiparallel β-sheet  
Parallel β-sheet  
Turn  
Unordered 
1600–1690 
 
 
 
1650–1657 
1612–1640; 1670–1690 (weak)  
1626–1640 
1655–1675; 1680–1696 
1640–1651 
Amide II 
(CN stretching, NH bending) 
1480–1575 
Amide III  
(CN stretching, NH bending) 
1229–1301 
Amide IV  
(OCN bending) 
625–767 
Amide V  
(Out-of-plane NH bending) 
640–800 
Amide VI  
(Out-of-plane C=O bending) 
537–606 
Amide VII 
(skeletal torsion) 
200 
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Fig. 2. ATR-IR spectra of rituximab, p-SCN-Bn-DOTA-
rituximab, p-SCN-Bn-DTPA-rituximab and 1B4M-DTPA-
rituximab (unlabeled and lyophilized) 
 
 
 
 
 
 
Fig. 3. ATR-IR spectra of three types of BFCA-rituximab 
conjugates labeled with non-radioactive Lu or Y 
 
 
 
D. Gjorgieva Ackova, K. Smilkov, E. Janevik-Ivanovska, T. Stafilov, Z. Arsova-Sarafinovska, P. Makreski 
Maced. J. Chem. Chem. Eng. 34 (2), 351–362 (2015) 
356 
 
 
 
Fig. 4. Raman spectra of rituximab, p-SCN-Bn-DOTA-
rituximab, p-SCN-Bn-DTPA-rituximab and 1B4M-DTPA-
rituximab (unlabeled and lyophilized) 
 
 
 
 
 
 
Fig. 5. Raman spectra of three types of BFCA-rituximab  
conjugates labeled with non-radioactive Lu or Y
 Maced. J. Chem. Chem. Eng. 34 (2), 351–362 (2015) 
                 T a b l e  2 
 
Assignments of IR bands (cm
–1
) characteristic for the investigated rituximab immunoconjugates (labeled and unlabeled) 
 
Assignments 
Sample Amide VI  Amide IV and Amide V Amide III  Amide II Amide I 
Rituximab 537m
a; 545sh; 571w;  
584w; 591w 
627w; 636w; 647w; 671m 1235w 1459w; (1510w)b; (1540m); 
1561m 
(1620w); 1636w; (1647w); 
1655m; (1688w) 
p-SCN-Bn-DOTA-
rituximab 
538m; 570m; 585sh; 
591m 
670vw 1351s 1475vw; (1507w);1562w (1638m); (1656m); 1678w 
Lu-p-SCN-Bn-
DOTA-rituximab 
537m; 551s; 572m; 
592m 
628w; 651vw; 670m; 690w; 
718w; 735w; 758w 
1315vw 1472m; 1490m; (1508m);  
(1543m); 1558m; 1575m 
(1620w); 1640w; (1647w); 
(1656w); 1673m; (1684m) 
Y-p-SCN-Bn-
DOTA-rituximab 
551s; 561sh; 572s; 
591w; 606m 
671m; 700w; 720w; 741w; 
775w 
1215vw 1456m; 1472w; 1490w; 
(1508m);(1541m); 1560m 
(1620w); 1636m; (1648w); 
(1656w); (1684m) 
p-SCN-Bn-DTPA-
rituximab 
543w; 571w; 576m; 
592w 
648vw 1262vw (1543w); 1575w 1636w; (1656w); (1679w) 
Lu-p-SCN-Bn-
DTPA-rituximab 
546s; 552sh; 563m; 
573m; 591w 
636w; 670m; 722w; 742w 1205m 1475m; 1490w; (1510w); 
(1541w); 1561w; 1577w 
1637w; (1656w); 1684w 
Y-p-SCN-Bn-
DTPA-rituximab 
538sh; 540m; 561m; 
573m; 601w 
638m; 648w; 670m; 709w; 
728w; 758w; 797w 
/ 1474m; 1490m; (1508m); 
(1542w); 1560w; 1579w 
(1620w); 1637w; (1656w); 
(1684w) 
1B4M-DTPA-
rituximab 
538m; 545sh; 584w; 
592w 
628vw; 646w; 670m 1237vw 1460w; 1474vw;  
(1508w); (1543w); 1562m;  
1577w 
1637m; (1648w); 
1655s; 1677w; (1687m) 
Lu-1B4M-DTPA-
rituximab 
542m; 551m; 563m; 
572m; 592w; 600sh 
635w; 651w; 670m; 742vw 1205m 1474w; (1507m); (1545m); 
1559w; 1577w 
(1620w); 1640w; (1648w); 
1655w; 1673w; (1687w); 1699w 
Y-1B4M-DTPA-
rituximab 
538sh; 545s; 552sh; 
563sh; 572s; 600m 
636w; 643w; 670m;  
678w; 713w; 738w; 760w 
1270w 1475w; 1490w; (1507w); 
(1542m); 1559m; 1578m 
(1620w); 1637w; (1648w);  
(1686s) 
         a
vw: very weak, w: weak, m: medium, s: strong, vs: very strong, sh: shoulder;  
         b
frequencies given in parenthesis matching the literature data [20, 30, 31, 32]. 
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T a b l e  3  
 
Assignments of Raman bands (cm
–1
) characteristic for unlabeled and non-radioactive labeled-conjugated antibody 
 
Assignments 
Sample S-S Tyr  Trp  Tyr  Trp N-Cα-C Trp, Val Phe C-N Amide 
III 
Trp, Ca-H 
(def) 
C-H 
(def) 
Indole  
ring-Trp 
Tyr, Trp, 
Phe 
Amide I 
Rituximab 407ma; 416m; 
529w; 
(540m)b 
623w 
640m 
757s (840s); 
(854sh)  
(878w) 953sh  (958s); 
985w 
(1004s); 
(1012sh); 
(1031w) 
(1123w) (1245m) (1337w); 
1359w 
(1449s) (1554m)  1605w; 
(1614sh)  
(1670s) 
p-SCN-Bn-
DOTA 
-rituximab 
428m; 
(505m); 
(547sh); 
(555m) 
/ / (857sh)  886s (931sh)  (957s) (1010sh); 
1044w; 
1060w 
1112sh; 
(1126m)  
/ / / (1556vw) / (1671vw) 
Lu-p-SCN-
Bn-DOTA-
rituximab 
455m; 
(505m); 556s; 
574sh 
/ / (860m) / (937s) 990m (1002w); 
1062s 
(1128m); 
1174vw 
/ 1390vw / / / (1666vw) 
Y-p-SCN-
Bn-DOTA 
-rituximab 
402s; (505m); 
(540m); 
(553m); 584w 
/ / (859m) / (942s) 970sh 1065m (1128w) / / / / / (1663vw) 
p-SCN-Bn-
DTPA-
rituximab 
400m; 458w 
(505m); 557s; 
572m;  
/ / (864s)  / (929s) (980s) 1061s (1126s) 1213w 1355w (1445vw) / / (1671vw) 
Lu-p-SCN-
Bn-DTPA-
rituximab 
400m; 431w; 
(505w); 
(540m); 
557sh; 574w 
/ / (861sh)  (885s) 959s 982sh (1002w); 
1046m; 
1063sh 
1115w / / 1447vw / / (1663vw) 
Y-p-SCN-
Bn-DTPA-
rituximab 
404vw;  
503m; 555s; 
572m;  
/ / 823vw; 
(857sh)  
886m 934s  982sh 1060s (1128m) / / / / / (1675m) 
1B4M-
DTPA-
rituximab 
400m; 507w; 
555w; 
/ / 868s / 925sh; 
(932w) 
(978s) 1063m (1128w) / / / / 1609w (1671w) 
Lu-1B4M-
DTPA-
rituximab 
400m; 
(505m); 
556sh; 574m 
/ / (860m)  888m (930s) 961sh; 990m (1048sh); 
1062m 
(1132w) (1270w) / / / / (1673w) 
Y-1B4M-
DTPA-
rituximab 
400m; 
(505m); 
(538w); 
555w; 565w 
/ / (840sh); 
(857m)  
886w (944s) (978w) 1063m (1135m) 1228w 1357w 1406w 1568vw / (1675vw) 
avw: very weak, w: weak, m: medium, s: strong, vs: very strong, sh: shoulder;  
bfrequencies given in parenthesis matching the literature data [26, 31, 33, 34, 35]. 
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The correlation between the band frequency 
and the secondary structure of the protein arises 
from the fact that the hydrogen bonding between 
the polypeptide bonds is different in α-helix, β-
sheet, or disordered structures [34]. An antibody 
molecule predominantly consists of β-sheet (47%), 
α-helices (7%), and turns and coils (the remaining 
percentage) [36]. The following three signals are 
most significant for the identification of different 
protein backbone confirmations: amide I (stretch-
ing vibration of C=O), amide II and amide III 
(both associated with coupled C–N stretching and 
N–H bending vibrations of the peptide bond) [37]. 
Typical β-sheet proteins, as monoclonal antibodies, 
show a characteristic Amide I band at around 
1650–1690 cm–1 which is the most sensitive spec-
tral region and consists of overlapping component 
bands, originating from α-helices, β-sheets, turns 
and random structures. 
Here, we observed that investigated protein 
components regain their native conformation upon 
rehydration (reversible unfolding). A strong band 
in the region between 1612 and 1640 cm
–1
 and a 
weaker band around 1685 cm
–1
 are commonly ob-
served for β-sheets, although weak bands at lower 
frequencies (1665–1670 cm–1) have also been de-
tected [31]. For all samples, unlabeled and labeled 
rituximab conjugates, we detected predominantly 
bands characteristic for β-structure (Tables 2 and 
3), which is in accordance with the previously pub-
lished data [30, 31, 38, 39]. Furthermore, proteins 
known to adopt α-helical conformation have strong 
amide I bands between 1650 and 1655 cm
–1
. In all 
studied samples, bands at 1655 or 1656 cm
–1
 were 
detected, pointing out that α-helices are present in 
the structure. The existence of non-ordered (or 
random) structure is evidenced from the IR band 
with the centroid around 1645 cm
–1
. In the corre-
sponding spectra of rituximab as well as in the 
spectra of all p-SCN-Bn-DOTA- and 1B4M-
DTPA-conjugates, bands at 1647 or 1648 cm
–1
 
were detected, which revealed the presence of non-
ordered structure in the molecule.  
The appearance of a singlet Raman band 
around 1670 cm
–1
 (Table 3) is explained by the fact 
that amide I band of turns overlaps and overlays 
those of α-helices and β-sheets making its assign-
ment difficult. Although the presence of unordered 
or random structure in the conjugates from the IR 
spectra is generally assigned according to the band 
at around 1645 cm
–1
, the corresponding Raman 
band is blue-shifted to 1665 cm
–1
. The bands ap-
pearing at higher frequencies are attributed to the 
α-helix vibrations in the structure. 
According to the previously published data 
[31], a strong amide II band in the IR spectra of 
proteins is observed in the 1540–1550 cm–1 region 
accompanied by a weaker shoulder at 1510–1525 
cm
–1. Components with an antiparallel β-sheet 
structure exhibit strong amide II bands between 
1510 and 1530 cm
–1
, whereas somewhat higher 
frequencies (1530–1550 cm–1) point to the parallel 
β-sheet structure. Indeed, in the 1507–1510 cm–1 
region, we detected the bands attributed to the an-
tiparallel β-sheet structure whereas the bands regis-
tered around 1540 cm
–1
 unveil the parallel β-sheet 
structure. In corresponding Raman spectra, bands 
are overlapped with the bands of other side chain 
groups (aromatic amino acids) (Table 3).  
The amide II and amide III bands, when 
used in combination with the amide I band, may 
help to assign the protein structure enabling a more 
accurate estimation of the helix and the random 
components (Amide II), as well as a distinction 
between β and disordered structures (Amide III) 
[31]. Generally, based on the band frequencies ob-
tained for amide I, II and III bands, the studied 
compounds contain a higher percentage of β-sheet 
conformation (antiparallel and parallel) in the 
structure, followed by α-helices.  
The weak intensity of the IR amide III band 
is due to its occurrence in a region where other 
mixed vibrations (CH bending, tyrosine and phe-
nylalanine ring vibrations) appear. Bearing in mind 
the weaker intensity of the Raman bands ascribed 
to the latter vibrations, the corresponding amide III 
band is much more pronounced in the Raman spec-
tra (see Table 3).  
In addition to characterization of the amide 
bands, Raman spectroscopy enables the detection 
and assignment of numerous bands from the amino 
acid groups. Marker bands of aromatics in proteins 
are relatively strong and well recognized, but under 
some circumstances, they can be overlapped with 
bands of amides and other side chain groups [26]. 
For example, a typical protein exhibits about 30 
Raman bands in the region between 2000 and 400 
cm
–1
 and additional bands in the 4000–2500 cm–1 
interval that are due to the vibrational modes of 
localized groups such as -NH, -OH, -CH3, -CH2, 
and -SH [26, 34, 40]. Still, the best defined Raman 
bands in the protein aromatics are those arising 
from phenylalanine (Phe), tryptophan (Trp) and 
tyrosine (Tyr) (Table 3). The majority of proteins, 
antibodies among them, contain either free sulf-
hydryls (–C–SH or R–SH) or disulfide groups (or 
both) [26]. The appearance of the disulfide bonds 
in the Raman spectra in the low frequency region 
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between 700 and 400 cm
–1 
was also detected (see 
Fig. 4, Fig. 5 and Table 3).  
The unfolding and misfolding of proteins is 
an important issue in retaining pharmaceutical sta-
bility and the activity of proteins. Denaturation of 
the native structure, misfolding and subsequent 
aggregation regularly include a change in the sec-
ondary structure. The aggregation of proteins is a 
problem with serious pharmaceutical/medical im-
plications and therefore, vibrational spectroscopy 
techniques are valuable for studying the aggrega-
tion processes of a wide range of proteins. The 
thermally-induced aggregation processes of the 
majority of proteins studied by FT-IR and Raman 
spectroscopy can be described with a two-state 
model: the predominant secondary structural ele-
ment (α-helix or β-sheet) decreases as a function of 
temperature and is concomitantly replaced by in-
termolecular aggregates [26, 32]. 
The appearance of strong absorption bands 
below 1620 cm
–1
 can be correlated with aggrega-
tion, which is usually associated with the formation 
of strong beta-sheet structures [41]. It is worth 
mentioning that we observed the retention of the 
native structure of the antibody and no obvious 
aggregation (the lowest band frequency detected 
was 1620 cm
–1
 with weak intensity) (Table 2, Fig. 
2 and Fig. 3) occurred in the samples according to 
the obtained spectra of all labeled and unlabeled 
conjugates after lyophilization.  
However, as shown in Figures 2–5, depend-
ing of the chelator type of immunoconjugate, fre-
quency shifts for some of the characteristic bands 
occurred in the recorded spectra, but it is clear that 
the chelating agents used do not provoke signifi-
cant changes in the secondary structure of the anti-
body. Namely, the immunoconjugate spectra 
showed peak shifts and intensity variations that 
could be attributed to conformational changes that 
occur during conjugation and labeling. Several key 
spectral areas can be identified, which is consistent 
with the fact that specific amino acids are shielded 
from undergoing conjugate formation, while some 
new amino acid residues are made visible in the 
spectrum of the immunoconjugates. This is evi-
denced by the band loss or decrease in band num-
ber in the spectral region of aromatic amino acids 
(Trp and Tyr) in conjugate spectra (labeled and 
unlabeled), compared to rituximab spectra (Table 
3), and could be a result of conformational binding. 
In the immunoconjugates formed, a decrease in 
tryptophan residues at 757, 878 and 1337 cm
−1
 was 
noted. 
Upon formation of the immunoconjugates 
(labeled and unlabeled), the most noted Raman 
peak shift occurred between 540–400 cm−1, which 
can be attributed to conformational changes 
through vibrations of the disulfide bonds. In the 
Amide III region, a peak shift (in IR) or loss (in 
Raman spectra) of the immunoconjugate may also 
correspond to conformational changes. The differ-
ences which can be observed in Figures 2–5 sug-
gest that the immunoconjugate formation could 
result in changes to the conformation after binding, 
the orientation of bonds, and shifts in the intensity 
of functional group bands. Additionally, new peaks 
which are not found in the antibody spectra indi-
cate complex formation. 
Based on the frequencies assigned for amide 
I, II and III bands, the studied compounds contain 
the highest percentage of β-sheet conformation (an-
tiparallel and parallel) in the structure, followed by 
α-helices. Significant changes were not observed 
upon conjugation and freeze-drying procedures.  
These results indicate that vibrational spec-
tra can be used to identify binding events and as-
sign the obtained frequencies to a particular event 
in the structure. In addition, amide bands in the 
obtained vibrational spectra could be used as an 
analytical tool which enables a quick and reliable 
way for screening protein pharmaceuticals during 
the development of lyophilized formulations. 
Vibrational spectroscopic data allow the detec-
tion of alterations in protein structural models as well 
as the rapid assessment of conformational changes 
resulting from ligand binding, aggregation or mac-
romolecular interactions. Knowing which part(s) of a 
protein adopt a particular secondary structure is im-
portant for deciding whether these protein pharma-
ceuticals meet the given criteria and is critical for 
almost all protein-modeling approaches.  
In summary, we investigated the potential 
application of vibrational spectroscopy in the as-
sessment of conformational changes during stress 
conditions, such as lyophilization and non-radio-
active labeling, using rituximab as a model anti-
body. We obtained IR and Raman spectra of the 
immunoconjugates that are somewhat different 
from those of the parent antibody. Peak shifts and 
intensity variations observed could be attributed to 
conformational changes that occur during conjuga-
tion and labeling and it is possible to assign these 
changes to complex formation. These results pro-
vide a good foundation for further radiolabeling 
studies of the kit formulations for possible thera-
peutic applications.  
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